ADELAIDE, Australia / RankWire.AI / – Researchers in Australia have pinpointed a molecular switch that influences how aggressive tumors spread, revealing a possible route for therapy to prevent secondary cancers. Published in EMBO Molecular Medicine, scientists from Adelaide University and the Olivia Newton-John Cancer Research Institute showed that restoring a critical regulatory molecule called miR-342 dramatically decreases tumor dissemination. The study’s results suggest that Australian scientists have identified an innovative approach to fighting triple-negative breast cancer by targeting dormant cancer cells before they develop into life-threatening lesions in distant organs.
Although triple-negative breast cancer accounts for 10% to 15% of Australia’s approximately 21,000 yearly breast cancer diagnoses, it leads to a disproportionate number of fatalities. This form of cancer lacks estrogen, progesterone, and HER2 receptors, making conventional targeted hormone therapies ineffective. The lead researchers demonstrated that when miR-342 levels decline, a cancer-promoting pathway known as E2F becomes overly active, enabling dormant cancer cells to spread and form dangerous secondary tumors throughout the body.
Targeted Treatments Bring New Possibilities for High-Risk Metastasis Prevention
In pre-clinical models, boosting miR-342 levels substantially reduced cancer cell spread to distant organs. Researchers also found that palbociclib, an existing CDK4/6 inhibitor drug already approved for hormone receptor-positive breast cancers, significantly slowed metastatic tumor growth in models with low miR-342 levels. These findings imply that measuring miR-342 could enable clinicians to repurpose current drugs for treating patients at high risk.
Associate Professor Philip Gregory, co-senior author from Adelaide University’s Centre for Cancer Biology, confirmed that halting metastasis remains the biggest challenge in treating aggressive breast cancers. Gregory emphasized that because palbociclib targets the overactive E2F pathway, administering it after cancer cells have spread prevents tiny deposits from enlarging. Instead of only shrinking primary tumors, this approach aims to stop microscopic secondary cancers from progressing into life-threatening conditions.
Published Pre-Clinical Results in Peer-Reviewed EMBO Molecular Medicine
The research team observed that triple-negative breast cancer is biologically heterogeneous, which has historically complicated the development of universal targeted treatments. By identifying a specific biological vulnerability common among a particular patient subgroup, their study paves the way for personalized treatment strategies. As Australian researchers work to confirm these findings using patient-derived models before moving into clinical trials, hope for improved therapies grows.
The results have been welcomed by medical oncologists and cancer research organizations across Australia, who stress the urgent need for expanding treatment options when primary therapies fail. The research team aims to collaborate with international clinical networks to speed up biomarker screening. Validating miR-342 testing could soon allow doctors to identify suitable candidates for early targeted CDK4/6 inhibitor therapies.